EGFR and non-small cell lung carcinoma: EGFR-tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib [22], erlotinib [23], afatinib [24], dacomitinib [25] and osimertinib [26] are treatment options as a first-line therapy for advanced NSCLC patients with EGFR mutations [27,28,29,30].